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Abstract
Background: Case–control studies suggest that patients with allergic diseases have a
lower risk of developing glioma but not meningioma or schwannoma. However,
those data can be differentially biased. Prospective studies with objective measure-
ments of immunologic biomarkers, like immunoglobulin E (IgE), in blood obtained
before cancer diagnosis could help to clarify whether an aetiological association
exists.
Methods: The present case–control study nested within the European Prospective
Investigation into Cancer and Nutrition (EPIC) measured speciﬁc serum IgE as a
biomarker for the most common inhalant allergens in 275 glioma, 175 meningioma
and 49 schwannoma cases and 963 matched controls using the ImmunoCAP speciﬁc
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Only high dose ionizing radiation and genetic predisposition
are established risk factors for primary brain tumours (1–4).
To date, the results from case–control studies have shown an
inverse association between glioma and allergies; however,
the results have been less consistent for meningioma (5–9).
Cohort studies have also provided conﬂicting results. A
Swedish register-based cohort study, which included younger
and older participants (median age of 30 and 54 years,
respectively), found that glioma and meningioma increased
risks of the younger and decreased risks of the older age
group (10). A further register-based retrospective cohort
study reported a positive association between atopic dermati-
tis and all brain tumours (11), whereas other cohort studies
showed no association with allergies (12, 13).
At present, no conclusive biological mechanism is known
for the suggested link between allergy and brain tumour
development (14). According to one hypothesis, the immune
system continuously recognizes and destroys tumour cells
(15). Thus, a hyper-active immune system of allergic persons
would lead to an enhanced tumour immune surveillance.
Whether this applies to brain tumours is currently not
known.
Most studies of allergies and brain tumours used question-
naire data; hence, allergies were self-reported (5, 7, 16–18)
and could therefore be inﬂuenced by recall biases or differen-
tial misclassiﬁcation. Only one case–control and one cohort
study deﬁned the atopic status of the study participants by
measuring total serum IgE levels in glioma cases and controls
in addition to the questionnaire data (10, 19) and another
cohort study used a skin prick test (12). However, it is known
that not all persons with atopic conditions actually express
allergic symptoms. Using a biomarker, like IgE, instead has
the advantage of detecting atopic predisposition indepen-
dently of clinical symptoms. Speciﬁc serum IgE are indicative
of allergic sensitization to speciﬁc (environmental) allergens
but might also be inﬂuenced by the immunological situation
during cancer development. Therefore, the measurement of
biomarkers like IgE at the time of tumour diagnosis might be
affected by the cancer disease.
The aim of the present nested case–control study was to
investigate for the ﬁrst time in a large prospective study set-
ting the association between IgE levels and primary brain
tumours (glioma, meningioma and schwannoma). Because of
the lack of sufﬁcient data for nutritional allergies from this
study, we focus here on the most common inhalant allergens
for which a valid test is available. Serum samples were pro-
spectively collected in the framework of a large international,
multi-centric prospective cohort study – the European Pro-
spective Investigation into Cancer and Nutrition (EPIC).
Materials and methods
The EPIC cohort
The EPIC cohort study investigates associations between can-
cer, or other chronic diseases and nutritional habits, lifestyle
and environmental factors; 521 457 men and women mainly
aged 35–70 years are included, from 23 study centres in ten
European countries: Denmark (Aarhus, Copenhagen),
France, Germany (Heidelberg, Potsdam), Greece, Italy (Flor-
ence, Naples, Ragusa, Turin, Varese), the Netherlands (Bil-
thoven, Utrecht), Norway, Spain (Asturias, Granada,
Murcia, Navarra, San Sebastian), Sweden (Malmo¨, Umea)
and the United Kingdom (Cambridge, Oxford).
A detailed description of the design of the EPIC study, its
study population, baseline data collection and follow-up pro-
cedures for cancer incidence and vital status has been given
elsewhere (20). Brieﬂy, recruitment took place between 1992
and 1998. Besides the collection of questionnaire data, also
personal interviews about medical, occupational and lifestyle
factors were conducted. In addition, about 386 000 partici-
pants provided a blood sample at or near recruitment.
The present study measured serum-speciﬁc IgE antibodies
as a biomarker for allergic sensitization and investigated the
relationship to the incidence of primary brain tumours. Data
and serum samples of cases and controls from all but France
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IgE test. Subjects with an IgE level ‡0.35 kUA/l (kilo antibody units per litre) were
classiﬁed as sensitized by allergens. Odds ratios (OR) and 95% conﬁdence intervals
(CI) were estimated by adjusted conditional logistic regression models for each
tumour subtype. The effect of dose–response relationship was assessed in ﬁve
increasing IgE level categories to estimate P-values for trend.
Results: The risk of glioma was inversely related to allergic sensitization
(OR = 0.73; 95% CI 0.51–1.06), especially pronounced in women (OR = 0.53;
95% CI 0.30–0.95). In dose–response analyses, for high-grade glioma, the lowest
OR was observed in sera with the highest IgE levels (P for trend = 0.04). No asso-
ciation was seen for meningioma and schwannoma.
Conclusion: The results, based on serum samples prospectively collected in a cohort
study, provide some support for the hypothesis that individuals with allergic sensiti-
zation are at reduced risk of glioma and conﬁrm results from previous case–control
studies.
Abbreviations
95% CI, 95% confidence interval; EPIC, European Prospective
Investigation into Cancer and Nutrition; HGG, high-grade glioma;
ICD-O, International classification of diseases for oncology; IgE,
immunoglobulin E; kUA/l, kilo antibody units per litre; LGG, low-
grade glioma; OR, odds ratio.
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and Norway EPIC centre were used. Incident cases were
identiﬁed by cancer registries through record linkage (Spain,
Italy, the Netherlands, UK, Denmark and Sweden) or by
active follow-up (Germany and Greece). Data on vital status
were collected by linkage with mortality registries or by letter
contact during follow-up. Participants of the cohort were
censored between December 2002 and December 2005. For
Germany and Greece, the end of follow-up was considered to
be the last known contact, date of diagnosis, or date of
death, whichever came ﬁrst.
From all participants who gave written consent, a 30 ml
blood sample was collected according to a standardized pro-
tocol (detailed description see elsewhere) (20). All centres, but
Sweden and Denmark, sent blood fractions (serum, plasma,
red cells and buffy coat for DNA extraction) to the EPIC
Biobank at IARC Lyon, where they are stored. Danish and
Swedish samples were stored locally. The median time
between blood sampling and diagnosis was 3010 days
(8.24 years); with a range of 29–4981 days.
The study was approved by the local ethics committees in
all participating countries and the Internal Review Board of
the IARC, Lyon, France (20). All information allowing the
identiﬁcation of the participants was removed from the study
data base used for data analyses. Serum used in laboratory
analyses was labelled using anonymous codes.
Selection of cases and controls
Brain tumour cases of the EPIC cohort were deﬁned as those
diagnosed with a primary brain tumour as the ﬁrst cancer
after recruitment date and before censoring date. Of 696
tumour cases with histological conﬁrmed diagnosis 372 were
glioma cases [International classiﬁcation of diseases for
oncology (WHO, 2000); ICD-O codes M9380–M9473], 253
were meningioma cases (ICD-O M9530-M9539), and 71 sch-
wannoma cases (ICD-O M9540 (21). In addition, glioma
cases were divided into high-grade glioma (HGG), (ICD-O
codes: M9440/3, M9441/3, M9442/3, M9401/3, M9380/3,
M9451/3) and low-grade glioma (LGG), (ICD-O codes:
M9382/3, M9383/1, M9384/1, M9390/0, M9394/1, M9400/3,
M9411/3, M9420/3, M9421/3, M9450/3, M9505/1, M9391/3).
Overall, 1188 control subjects free of cancer and with
available blood samples were identiﬁed. Two control subjects,
selected randomly from the EPIC cohort, were matched to
each case according to study centre, gender, data of birth
(±1 year), age at blood collection (±6 months), date of
blood collection (±1 month), time of blood collection
(±1 h) and length of follow-up.
Laboratory method
The immediate (atopic or anaphylactic) type of allergy is a
function of serum antibodies belonging to the IgE class of
immunoglobulins (22, 23). Speciﬁc IgE antibodies were mea-
sured by the ImmunoCAP speciﬁc IgE test (Phadia AB, Upp-
sala, Sweden), a well-established in vitro quantitative
measurement used for the determination of IgE in serum or
plasma; however, the test focus on the detection of inhalant
allergens. According to Vidal et al. (24), the test has a sensi-
tivity of 70.8% (95% CI 61.7–78.6%) and a speciﬁcity of
90.7% (95% CI 87.0–93.5%) tested in an unselected adult
sample, and tested in symptomatic patients 79.2% (95% CI
68.2–87.3%) and a speciﬁcity of 91.6% (95% CI 85.6–95.4%)
and allows detection of very low concentrations of IgE anti-
bodies (23, 25, 26). It allows quantitative measurements [in
kilo antibody units per litre (kUA/l)] of speciﬁc antibodies
against a mixture of the eight most common respiratory aller-
gens, including those with the international allergen codes:
g6-timothy grass, g12-cultivated rye, t3-common silver birch,
w6-mugwort, d1-Dermatophagoides pteronyssinus, e1-cats
epithelium and dander, e5-dog dander, m2-Cladosporium
herbarum.
Using the UniCap 100 apparatus (Phadia AB, Uppsala,
Sweden), each standardized test needed 40 ll serum or
plasma from the respective participant. The concentration of
speciﬁc IgE was determined automatically according to the
instructions of the ImmunoCap (Phadia AB, Uppsala, Swe-
den) using ‡0.35 kUA/l as the cut-off for a positive value.
Finally, because of missing of blood samples for testing
and invalid IgE measurements (n = 46), speciﬁc IgE serum
levels could be determined in 1462 blood samples. Thus, sta-
tistical analyses included 275 glioma cases and 528 controls,
175 meningioma cases and 343 controls, and 49 schwannoma
cases and 92 controls.
Statistical analyses
Odds ratios (OR) and 95% conﬁdence intervals (CI) were
calculated for all brain tumour subtypes, using conditional
logistic regression models (27) (LOGISTIC procedure of the
SAS software package, Version 9.1; SAS Institute, Inc., Cary,
NC, USA). Separate analyses have been performed for men
and women because of considerable gender differences in
brain tumour subtypes.
Adjustments were made in all analyses for educational
level (primary school or less, technical/secondary school, uni-
versity degree and not speciﬁed or none educational degree)
and for smoking status (never, former, current, unknown).
Alcohol consumption (never, former, only at recruitment,
lifetime, unknown), physical activity (inactive, moderately
inactive, moderately active, active, unknown) and hormone
replacement therapy (HRT) for women had only marginal
inﬂuence on the risk estimates (<10%) and were therefore
not retained in ﬁnal models.
According to the cut-point of ‡0.35 kUA/l, speciﬁc IgE lev-
els were divided into a ‘positive’ group and a ‘negative’ group.
Dose–response relationships were estimated using sub-catego-
ries within the positive group as follows: ‘borderline positive’
(‡0.35–0.7), ‘weak positive’ (‡0.7–3.5), ‘strong positive’ (‡3.5–
17.5), and ‘very strong positive’ (‡17.5 kUA/l). In addition,
the P-value for trend across these categories was estimated by
assigning each category its median level of speciﬁc IgE.
Before pooling the data of the different centres, a chi-
square-test for heterogeneity was performed, a P-value of
<0.05 was considered as evidence for heterogeneity between
centres.
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Sensitivity analyses were performed for the speciﬁc IgE
level measurements by excluding cases that were diagnosed
with their brain tumour within 2 years and their matched
controls to exclude the possibility of reverse causation. Fur-
thermore, analyses for glioma and meningioma were con-
ducted with respect to the location of the tumour in the
brain cavity or in the spinal cord (glioma – ICD-O topogra-
phy code C71.0–C71.9 or C72.0; respectively meningioma
ICD-O topography code C70.0 or C70.1 or C70.9) without
seeing major differences, and location therefore was ignored
in the analyses.
Results
Baseline characteristics of the study participants are shown in
Table 1. Marginal differences were found for education and
smoking habits among glioma or meningioma cases and con-
trols, whereas schwannoma cases had attained more educa-
tion compared with their controls.
An inverse association was found between all glioma and
allergic sensitization (OR = 0.73; 95% CI 0.51–1.06)
(Table 2). ORs were signiﬁcant only for women (OR = 0.53;
95% CI 0.30–0.95), especially for those with HGG
(OR = 0.45; 95% CI 0.21–0.96). For men, the effects were
weaker; however, the CI is widely overlapping with those for
women. When positive speciﬁc IgE levels were stratiﬁed by
concentrations of IgE, the lowest OR for glioma was seen in
the highest (‘very strong positive’) category. For HGG in
men and women combined, but not for LGG, the higher the
intensity of the speciﬁc IgE the lower the OR (trend analyses:
P = 0.04).
Excluding those cases, and their matched controls, with a
follow-up time between IgE measurement and tumour diag-
nosis of <2 years, weakened the effect for glioma; however,
the trend for the intensity of the IgE levels and HGG was
marginally signiﬁcant (P-value 0.06).
For meningioma no associations were found, including
intensity of speciﬁc IgE levels. No association between spe-
ciﬁc IgE levels and schwannoma risk were observed
(Table 3).
Discussion
This is the ﬁrst study using data collected in participants of a
prospective cohort study to investigate the atopic status
(determined by measured IgE levels) in a large sample of
cases with primary brain tumours. An inverse association
between allergic sensitization and glioma occurrence was
found for pre-diagnostic speciﬁc serum IgE categories,
whereas no association was observed for meningioma. HGG
showed an inverse trend of decreasing risk with increasing
IgE concentrations.
Characteristics of cases in all brain tumour subtypes in this
cohort were similar as expected based upon previous studies
Table 1 Description of glioma, meningioma and schwannoma cases and controls in respect to age, specific IgE categories, gender, educa-
tion and smoking status. Case–control study nested into the European Prospective Investigation into Cancer and Nutrition cohort (EPIC)
Glioma Meningioma Schwannoma
Cases Controls* Cases Controls Cases Controls
N (%) N (%) N (%) N (%) N (%) N (%)
Total numbers 275 (100) 528 (100) 175 (100) 343 (100) 49 (100) 92 (100)
Age (years, mean) 55.35 55.34 54.92 54.89 55.53 55.54
Serum specific IgE level§
‡0.35 kUA/l 59 (21.5) 141 (26.7) 38 (21.7) 78 (22.7) 10 (20.4) 21 (22.8)
<0.35 kUA/l 216 (78.5) 387 (73.3) 137 (78.3) 265 (77.3) 39 (79.6) 71 (77.2)
Gender
Male 136 (49.5) 261 (49.4) 43 (33.3) 132 (33.9) 17 (34.7) 31 (33.7)
Female 139 (50.5) 267 (50.6) 86 (66.7) 257 (66.1) 32 (65.3) 61 (66.3)
Highest education level
Primary school 98 (35.6) 174 (33.0) 72 (41.1) 113 (32.9) 12 (24.5) 32 (34.8)
Tech/secondary school 111 (40.4) 220 (41.7) 71 (40.6) 163 (47.5) 25 (51.0) 37 (40.2)
University 55 (20.0) 112 (21.1) 26 (14.9) 54 (15.8) 9 (18.4) 17 (18.5)
Unknown 11 (4.0) 22 (4.2) 6 (3.4) 13 (3.8) 3 (6.1) 6 (6.5)
Smoking status
Never 125 (45.5) 245 (46.4) 87 (49.7) 182 (53.1) 27 (55.0) 43 (46.7)
Former 87 (31.6) 156 (29.6) 46 (26.3) 79 (23.0) 11 (22.5) 24 (26.1)
Current 61 (22.2) 118 (22.3) 40 (22.9) 77 (22.4) 11 (22.5) 25 (27.2)
Unknown 2 (0.7) 9 (1.7) 2 (1.1) 5 (1.5) 0 0
*22 controls are missing.
Seven controls are missing.
Six controls are missing.
§Cut points: specific IgE level ‡0.35 kUA/l = positive; specific IgE level <0.35 kUA/l = negative.
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(5, 6, 16). The slightly higher number of glioma in women
reﬂects the larger proportion of women in the overall EPIC
cohort population. The study design of the case–control
study nested in the EPIC cohort allowed for investigating
speciﬁc IgE values in pre-diagnostic blood samples for the
speciﬁc IgE values which were only collected at the time of
enrolment into the cohort; thus, we could not analyse longi-
tudinal changes. Our results support those from case–control
studies based on self-reported allergic diseases (5–7, 16, 17,
28–32) and especially those of one case–control study using
IgE measurement at the time of tumour diagnosis (19).
In two case–control studies, associations between age at
onset or duration of allergies (in years) and glioma risk were
investigated using questionnaire data, but with conﬂicting
results (16, 18). In one cohort study (10), a reanalysis of data
from individuals who reported allergies 5 years before a diag-
nosis of brain tumours were similar to results of the whole
cohort. Berg-Beckhoff et al. (18) show that asthma, eczema
and hay fever together (‘allergic condition’) were inversely
associated with glioma or meningioma diagnosis when the
duration was <10 years prior the brain tumour diagnosis.
Overall, we found no signiﬁcant association between aller-
gic sensitization and meningioma or schwannoma, which is
in agreement with the results of most case–control studies (5–
7, 16, 28, 30). Gender-speciﬁc analyses showed inconsistent
results for all tumour types. We assume that these results
might be because of chance, probably small sample sizes have
led to low precision of some of the estimates. Additional
adjustments, e.g., for HRT or education did not alter the
risks.
For brain tumours, only high doses of ionizing radiation
and some hereditary conditions are conﬁrmed risk factors,
but results from most case–control studies have also quite
consistently shown an inverse association between allergic
diseases and glioma. Our results support observations of
case–control studies insofar that speciﬁc IgE levels overall
show a negative association with glioma risk (17); however,
taking into account a 2-year latency, this association was
somewhat weakened. One explanation for the inverse associa-
tions between a history of atopic disease and cancer risk is
the immuno-surveillance hypothesis, proposed ﬁrst in 1970
by Burnet (15). This hypothesis states that the immune sys-
tem protects the host against the development of cancer.
Another explanation might be reverse causality, which means
that the observed association might be due to the suppression
of the immune system by the tumour itself. For brain
tumours, it is accepted that some of them have a long pre-
diagnostic period (e.g. meningioma, LGG), but HGG seems
to have a relatively short progression period. In addition, gli-
oma patients are known to have immunological defects such
as abnormal delayed hypersensitivity responses, low number
of circulating T-cells, decreased antibody response and
impaired T-cell cytotoxicity (33, 34). Our results based on
prospectively collected data cannot give a conclusive answer
which hypothesis might be favoured, but for HGG our data
provide some support for the immune surveillance hypothe-
sis. Whether this is because of a stronger reaction of the
immune system of HGG patients on environmental inﬂuences
(compared with LGG patients) or vice-versa is at this stage
only speculative. However, our result supports the observa-
tion of Sherman et al. (35) who noted that an inverse associa-
tion with allergies were more often found for cancer of
different tissues, including brain tissue, and organ systems
that interface with external environment than in those tissue
that do not so. The site speciﬁcity of the association between
allergies and cancer is also described in a review by Merill et
al. (2007) (36).
The timing between the onset of alteration of atopic sensi-
tization (e.g. measured by speciﬁc serum IgE) and tumour
development might be an important issue. However, studies
where biomarkers were determined in biological specimens
obtained at the time of tumour diagnosis cannot ascertain
whether the tumour itself inﬂuenced the immune system.
Because of the uncertainty of tumour latency, even the pres-
ent study which used prospectively collected blood samples
many years before brain tumour diagnosis is not conclusive,
because only the date of diagnosis and the date of recruit-
ment into the cohort as reference dates could be used to esti-
mate how long the atopic status was present prior to cancer
diagnosis.
One of the main strengths of this study is the use of an
allergy biomarker for allergic sensitization (speciﬁc IgE)
instead of self-reported data on allergy from questionnaires.
The ImmunoCap test (Pharmacia AB, Uppsala Sweden) is
one of the standardized tests for atopy in medical diagnostics
(25, 26), covering about 70–80% of the most common eight
inhalant allergens in Europe. In addition, there is no evidence
that the speciﬁc IgE concentration is inﬂuenced by gender
and also the lower OR observed by Berg-Beckhoff et al. (18)
in children with a history of allergy compared with adults
have not been conﬁrmed until now. The IgE categories are
known to be very stable in blood samples over 17 years (23)
without any apparent degradation of IgE-deﬁned allergies.
All participants of our study are adults; their blood donation
took place less than 14 years ago, so that we do not expected
that our results were inﬂuenced by blood sample storage and
stability.
Atopic disposition does not necessarily lead to a clinically
relevant allergic disease. Studies on allergies using question-
Table 3 Adjusted* odds ratios (OR) and 95% confidence intervals
(95% CI) for schwannoma and specific IgE categories. Case–con-
trol study nested into the European Prospective Investigation into
Cancer and Nutrition cohort (EPIC)
Specific IgE
Schwannoma
Cases Controls
OR* 95% CIN N
All
Negative (<0.35 kUA/l) 39 71 1.00 –
Positive (‡0.35 kUA/l) 10 21 0.80 0.32–1.99
*OR are adjusted for highest education level and smoking status.
Chi-square test for heterogeneity: P = 0.89.
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naires will misclassify subjects without symptoms. Also, recall
bias might occur because of lack of diagnostic accuracy of
allergic diseases and differential recall bias because of mental
modiﬁcations, especially for glioma patients. Biomarker-
based studies using blood samples collected before tumours
diagnoses, like ours, may overcome some of these limitations.
The study was focused on inhalant allergies as there was lim-
ited information on nutritional allergies from the partici-
pants. In addition, although adjustment was made for
potential confounders, because of the observational nature of
this study, we cannot rule out the possibility of residual con-
founding.
In conclusion, to our knowledge, this is the ﬁrst study
based on speciﬁc IgE levels measured in pre-diagnostic serum
samples of brain tumour patients. This study support results
from previous observational studies showing an inverse asso-
ciation between glioma risk and allergies, although there was
a lack of statistical power to detect associations with rarer
subtypes of glioma. These results suggest that individuals
with biochemical evidence of allergic sensitization, especially
for inhalant allergens, may be at reduced risk of glioma. No
association was observed between IgE levels and meningioma
or schwannoma. Further studies based on multiple measure-
ments of immunological biomarkers including speciﬁc IgE
and, perhaps in combination with other biomarkers, will be
required to conﬁrm these results suggesting a relation
between immune system reaction and brain tumour develop-
ment.
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